Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals | Large Cap
Health Score : 6.86Torrent Pharmaceuticals demonstrates a mixed financial profile. The company exhibits strong solvency, driven by a low debt-to-equity ratio and robust interest coverage, suggesting a solid ability to manage its debt obligations. Growth prospects are also positive, fueled by increasing revenue and net income. Profitability metrics, such as gross profit margin and return on capital employed, are generally healthy, indicating efficient use of capital. However, efficiency ratios reveal challenges in inventory and receivable management. Liquidity is an area of concern, while financial ratios, particularly earnings per share and capital expenditures, are favorable. Overall, Torrent Pharmaceuticals shows potential for sustained growth, but needs to address liquidity and efficiency to enhance its financial stability.
Health Score : 6.86Torrent Pharmaceuticals demonstrates a mixed financial profile. The company exhibits strong solvency, driven by a low debt-to-equity ratio and robust interest coverage, suggesting a solid ability to manage its debt obligations. Growth prospects are also positive, fueled by increasing revenue and net income. Profitability metrics, such as gross profit margin and return on capital employed, are generally healthy, indicating efficient use of capital. However, efficiency ratios reveal challenges in inventory and receivable management. Liquidity is an area of concern, while financial ratios, particularly earnings per share and capital expenditures, are favorable. Overall, Torrent Pharmaceuticals shows potential for sustained growth, but needs to address liquidity and efficiency to enhance its financial stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
66.89
Industry Median
19.41
Large Cap Median
74.89
P/E RATIO
74.89
P/B RATIO
16.92
Industry Median
1.98
Large Cap Median
16.92
P/S RATIO
N/A
Industry Median
2.06
Large Cap Median
2.06
Others
PEG RATIO
5.43
EV/EBITDA RATIO
38.43
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹4229.1 as on Feb 20, 2026.
Growth Score : 6.40Torrent Pharmaceuticals shows promising growth prospects. The company has experienced noteworthy increases in revenue and net income. However, the negative earnings per share growth raises concerns about profitability at the shareholder level. Continued focus on innovation and market expansion could sustain growth momentum in the competitive pharmaceutical sector.
Revenue Growth RateAverageOperating Profit Growth RateAverageEarnings Per Share (EPS) GrowthPoor
Asset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue Growth Rate | N/A | N/A | N/A | N/A | N/A |
| Operating Profit Growth Rate | 14.29 | -1.98 | 16.91 | 18.51 | 10.48 |
| Earnings Per Share (EPS) Growth | 22.16 | -37.9 | 60.17 | 33.03 | 15.39 |
| Asset Growth Rate | N/A | -8.31 | 13.2 | -0.72 | -0.75 |
| Net Income Growth Rate | N/A | N/A | N/A | N/A | N/A |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Torrent Pharmaceuticals Ltd | 6.86 | 74.89 | Neutral | 3721.00 | 64.75 | 1911.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤13th Feb 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT
Concall Report⬤7th Nov 25
Q2 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
No Stock News Available at This Moment.
Torrent Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company, primarily engaged in developing, manufacturing, and marketing branded generics and specialty medicines. It operates across therapeutic areas like cardiovascular, CNS, gastro-intestinal, and women's healthcare, with a significant presence in India and international markets, holding a strong position in the domestic market.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Torrent Pharmaceuticals Ltd's P/E ratio (TTM) is 66.89, compared to the industry median of 19.41 and large cap median of 74.89.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Torrent Pharmaceuticals Ltd's P/B ratio is 16.92, compared to the industry median of 1.98 and large cap median of 16.92.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Torrent Pharmaceuticals Ltd's P/S ratio is 6.80, compared to the industry median of 2.06 and large cap median of 2.06.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Torrent Pharmaceuticals Ltd's PEG ratio is 5.43.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Torrent Pharmaceuticals Ltd's EV/EBITDA ratio is 38.43.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Torrent Pharmaceuticals Ltd's ROE is N/A.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Torrent Pharmaceuticals Ltd's ROA is N/A.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Torrent Pharmaceuticals Ltd's ROCE is N/A.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Torrent Pharmaceuticals Ltd's operating margin is N/A.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Torrent Pharmaceuticals Ltd's net margin is N/A.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Torrent Pharmaceuticals Ltd's current ratio is N/A.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Torrent Pharmaceuticals Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Torrent Pharmaceuticals Ltd's interest coverage ratio is 11.61.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Torrent Pharmaceuticals Ltd's DPS is ₹32.19.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Torrent Pharmaceuticals Ltd's EPS is 15.39.
(Source line: "Ratios as of 20 Feb 2026, based on last traded price of ₹4229.10. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1959
Headquarters: Ahmedabad, Gujarat
Core Offerings: Cardiovascular, Central Nervous System, Gastro-Intestinal, Diabetes Care, Women's Healthcare
Stock Listing: NSE (TORNTPHARM), BSE (500420)
Promoter: Torrent Group / Mehta Family
Founded in 1959 by U.N. Mehta, Torrent Pharmaceuticals established its R&D center in the 1980s, marking a commitment to innovation. The company aggressively expanded through strategic acquisitions, including Elder Pharma's domestic formulation business (2013), Unichem Laboratories' India and Nepal business (2017), and more recently, Curatio Health Care (2022). These moves have significantly strengthened its presence in the Indian market and key global geographies, evolving into a leading pharma player.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| India Formulations | 51% | Operating Profit |
| Brazil | 11% | Operating Profit |
| Germany | 11% | Operating Profit |
| USA | 7% | Operating Profit |
| Rest of World (RoW) | 20% | Operating Profit |
India Formulations: Focuses on chronic and acute therapies, leveraging a robust product portfolio, extensive field force, and strong brand recall in the domestic market.
International Business: Operates across key regulated and semi-regulated markets like Brazil, Germany, and USA, primarily dealing in branded generics and generics, supported by local manufacturing and marketing capabilities.
Research & Development: Invests significantly in R&D, focusing on new drug delivery systems, generic product development, and process innovation to maintain a competitive edge.
Mr. Samir Mehta: Chairman. Leads the Torrent Group, guiding its strategic direction across pharmaceuticals and power sectors with extensive industry experience. Mr. Aman Mehta: Managing Director. Responsible for driving the company's growth, operational excellence, and global expansion initiatives, with a focus on digital transformation and market penetration.
Torrent Pharma Inc. (USA)
Torrent Pharma GmbH (Germany)
Torrent Do Brasil Ltda. (Brazil)
Torrent Pharma (Malaysia) Sdn. Bhd.
Acquired Curatio Health Care Private Limited for ₹2000 crore in 2022, significantly enhancing its dermatology portfolio. The company regularly declares dividends to its shareholders.
The Torrent Pharmaceuticals Ltd share price today is ₹4229.10 on NSE (TORNTPHARM), as of 24 Aug 2026.
As of 20 Feb 2026, Torrent Pharmaceuticals Ltd share price is ₹4229.10, with previous close ₹N/A. Today's range is ₹N/A to ₹N/A. The 52-week range is ₹N/A to ₹N/A.
As of today, Torrent Pharmaceuticals Ltd's market cap is ₹1,42,943.58 crore (Large Cap).
Torrent Pharmaceuticals Ltd's current P/E ratio is 66.89, compared to the Pharmaceuticals & Biotechnology sector average of 36.
Torrent Pharmaceuticals Ltd's current P/B ratio is 16.92.
Torrent Pharmaceuticals Ltd's current dividend yield is 0.76%. Last dividend of ₹12.00 per share was declared on 24-May-2024.
Torrent Pharmaceuticals Ltd's EPS (TTM) is ₹15.39.
Torrent Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company, primarily engaged in developing, manufacturing, and marketing branded generics and specialty medicines. It operates across therapeutic areas like cardiovascular, CNS, gastro-intestinal, and women's healthcare, with a significant presence in India and international markets, holding a strong position in the domestic market.
Torrent Pharmaceuticals Ltd is promoted by Torrent Group / Mehta Family, holding 3,332.96% as of 20 Feb 2026.
Torrent Pharmaceuticals Ltd is listed on NSE (TORNTPHARM) and BSE (500420). Its next quarterly results are expected on August 2024.
Return on Capital Employed (ROCE)